Coronavirus Origin

Biological Profile of SARS-CoV-2

SARS-CoV-2 is a betacoronavirus in the family Coronaviridae. Its genome is a single-stranded, positive-sense RNA of approximately 29,900 nucleotides. The virus uses a spike (S) protein to bind the human ACE2 receptor, enabling cell entry. A distinctive feature is its furin cleavage site at the S1/S2 boundary — a characteristic not found in closely related bat coronaviruses and a focal point in the origin debate. ^[1]

The closest known relative is RaTG13, a bat coronavirus with ~96.2% genome similarity reported by Zhou et al. in Nature, collected from Yunnan Province, China. ^[2] Despite this similarity, 96% identity over a ~30,000-nucleotide genome still represents decades of evolutionary divergence.

What kind of claim each source is making

The origin debate mixes four very different kinds of statement, and most disagreement online comes from treating them as interchangeable.

• Peer-reviewed genomic and epidemiological analysis. Worobey et al. (Science, 2022) is spatial-epidemiological: it maps the earliest known cases and positive environmental samples onto the Huanan market and finds them clustered there, with two distinct lineages consistent with more than one introduction. This is evidence about where early transmission was amplified. Critics note that early case ascertainment itself was centred on the market, which is a genuine limitation rather than a dismissal.
• Peer-reviewed argument about plausibility. Andersen et al. (Nature Medicine, 2020) and Holmes et al. (Cell, 2021) argue from genome features about what is and is not consistent with engineering. Arguments of this form can establish that a feature has natural precedent; they cannot establish that it arose naturally in this case.
• Intelligence assessments. These are not scientific findings and do not carry scientific evidence with them. The Office of the Director of National Intelligence's June 2023 unclassified summary records a divided community: the Department of Energy favoured a laboratory-associated origin with low confidence, the FBI with moderate confidence, several other elements favoured natural exposure with low confidence, and others reached no conclusion. "Low confidence" is a term of art meaning the judgement rests on fragmentary or questionable information.
• Absence of evidence. No intermediate host animal has been identified, and no laboratory incident has been documented publicly. Neither absence is evidence for the other hypothesis. For SARS-CoV-1 the intermediate host took about four months to find; for MERS-CoV, several months; for Ebola, decades of searching have not conclusively identified the reservoir species.

What would actually settle it

Both hypotheses make checkable predictions, and the reason the question remains open is that the checks have not been possible rather than that they have failed.

• A progenitor virus in an animal population — a sampled animal carrying a virus closer to SARS-CoV-2 than the ~96.2% of RaTG13 reported by Zhou et al. in Nature, with a plausible trade route to Wuhan. This would be decisive for zoonotic spillover. It requires access to the pre-pandemic animal-trade supply chain and to stored samples.
• Serological evidence in the supply chain — antibodies in animal traders or farm workers predating the first recognised human cases. This was the route by which the SARS-CoV-1 civet link was established.
• Laboratory records — the Wuhan Institute of Virology's sample inventories, sequencing databases and staff health records from 2019. A laboratory origin would leave a documentary trace; so, importantly, would its absence.
• The earliest human samples. Blood-bank and hospital specimens from Wuhan in late 2019 would establish when human infection actually began, independent of which hypothesis is correct.

None of these has been available to independent investigators. The WHO's Scientific Advisory Group for the Origins of Novel Pathogens concluded in 2023 that the available data were not sufficient to determine how SARS-CoV-2 first infected humans, and called for further investigation — which is a statement about data access as much as about science.

What this site will not do

We will not describe either hypothesis as settled, will not treat an intelligence confidence level as a scientific finding, and will not present the number of scientists holding a view as though it were evidence. Where this page states a fact — the ~96.2% RaTG13 similarity (Zhou et al., Nature), the furin cleavage site, the two market lineages, the agency confidence levels (ODNI) — it names the specific source, and where the sources genuinely conflict, both appear above with their limitations attached.

The practical consequence of the origin question is largely about biosafety policy and pandemic preparedness rather than about anything a reader can act on today. For what is well established about how the virus spreads and what reduces risk, see our pages on variants, vaccines and treatment. The timeline page sets out the sequence of events in late 2019 and early 2020 that both hypotheses have to explain.